On June 24, 2016, Fournier, Jean-Francois; Clary, Laurence; Thoreau, Etienne published a patent.Quality Control of Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate The title of the patent was Preparation of heterocyclic compounds as GCRP receptor antagonist and their use in medicine and in cosmetics. And the patent contained the following:
The invention relates to heterocyclic compounds of formula I and their pharmaceutically acceptable salts, and their enantiomers. The invention also relates to their use as drug, preferentially in the prevention and/or the treatment of inflammatory diseases with a component neurogene or their use as cosmetic. The compounds of this invention act like antagonists of receiver CGRP-R. Compounds of formula I wherein Y is CH2, CO, C(CH3)2 and spirocyclopropyl; R1 is (un)substituted piperidinyl, azabicyclyl, azaspirocyclyl, etc.; R2, R3 and R6 are independently H, F and Me; R4 is H, alkyl, alkenyl, alkynyl, etc.; R5 is halo, alkyl, cycloalkyl, (un)substituted Ph, etc.; and pharmaceutically acceptable salts and enantiomers thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their GCRP receptor antagonistic activity. From the assay, it was determined that compound II exhibited Kdapp in the range of 10 nM – 100 nM. The experimental process involved the reaction of Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate(cas: 883984-95-0).Quality Control of Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate
The Article related to heterocyclyl preparation gcrp receptor antagonist, Heterocyclic Compounds (More Than One Hetero Atom): Diazepines and other aspects.Quality Control of Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate
Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem